Letters sent to healthcare professionals in July 2016

A summary of letters sent to healthcare professionals in July 2016 to inform of safety information for riociguat and for posaconazole.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 8 August 2016

• Therapeutic area: Cardiovascular disease and lipidology, Infectious disease and Respiratory disease and allergy

In July 2016, the following letters were sent to relevant healthcare professionals:

• riociguat (Adempas): not for use in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias. See also article in July 2016 issue of Drug Safety Update

• posaconazole (Noxafil): tablets and oral suspension are not interchangeable

Published 8 August 2016